|
1
|
Marchesini G and Marzocchi R: Metabolic
syndrome and NASH. Clin Liver Dis. 11105–117. (ix)2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fabbrini E, Sullivan S and Klein S:
Obesity and nonalcoholic fatty liver disease: Biochemical,
metabolic and clinical implications. Hepatology. 51:679–689. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song HY, Zhang L, Pan JL, Yang LL and Ji
G: Bioactivity of five components of Chinese herbal formula
Jiangzhi granules against hepatocellular steatosis. J Integr Med.
11:262–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stein LL, Dong MH and Loomba R: Insulin
sensitizers in nonalcoholic fatty liver disease and
steatohepatitis: Current status. Adv Ther. 26:893–907. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun L and Lü SZ: Association between
non-alcoholic fatty liver disease and coronary artery disease
severity. Chin Med J (Engl). 124:867–872. 2011.PubMed/NCBI
|
|
6
|
Zhao JS, Zhu FS, Liu S, Yang CQ and Chen
XM: Pioglitazone ameliorates nonalcoholic steatohepatitis by
down-regulating hepatic nuclear factor-kappa B and
cyclooxygenases-2 expression in rats. Chin Med J (Engl).
125:2316–2321. 2012.PubMed/NCBI
|
|
7
|
Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL
and Li JM: Peroxisome proliferator activated receptor-gamma in
pathogenesis of experimental fatty liver disease. World J
Gastroenterol. 10:1329–1332. 2004.PubMed/NCBI
|
|
8
|
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ,
Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional
fibrosis and steatohepatitis in mice. Scand J Gastroenterol.
44:358–365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lutchman G, Modi A, Kleiner DE, Promrat K,
Heller T, Ghany M, Borg B, Loomba R, Liang TJ and Premkumar A: The
effects of discontinuing pioglitazone in patients with nonalcoholic
steatohepatitis. Hepatology. 46:424–429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiu SL and Cline HT: Insulin receptor
signaling in the development of neuronal structure and function.
Neural Dev. 5:72010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Q, Xiao XH, Li M, Li WH, Yu M, Zhang
HB, Ping F, Wang ZX and Zheng J: Chromium-containing traditional
Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose
through activating insulin-signaling pathway and inhibiting PTP1B
and PCK2 in diabetic rats. J Integr Med. 12:162–170. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Samuel VT and Shulman GI: Integrating
mechanisms for insulin resistance: Common threads and missing
links. Cell. 148:852–8712012. View Article : Google Scholar
|
|
13
|
Mohammadi A, Gholamhoseinian A and Fallah
H: Zataria multiflora increases insulin sensitivity and
PPAR-γ gene expression in high fructose fed insulin resistant rats.
Iran J Basic Med Sci. 17:263–270. 2014.PubMed/NCBI
|
|
14
|
Rani S and O'Driscoll L: Analysis of
changes in phosphorylation of receptor tyrosine kinases: Antibody
arrays. Methods Mol Biol. 1233:15–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Promrat K, Lutchman G, Uwaifo GI, Freedman
RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, et al: A
pilot study of pioglitazone treatment for nonalcoholic
steatohepatitis. Hepatology. 39:188–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nesto RW, Bell D, Bonow RO, Fonseca V,
Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith
S, et al: Thiazolidinedione use, fluid retention, and congestive
heart failure: A consensus statement from the American Heart
Association and American Diabetes Association. Diabetes Care.
27:256–263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parulkar AA, Pendergrass ML, Granda-Ayala
R, Lee TR and Fonseca VA: Nonhypoglycemic effects of
thiazolidinediones. Ann Intern Med. 134:61–71. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang WJ: Enhancing the treatment of
metabolic syndrome with integrative medicine. J Integr Med.
11:153–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao Z, Zhang L and Ji G: Efficacy of
polyphenolic ingredients of Chinese herbs in treating dyslipidemia
of metabolic syndromes. J Integr Med. 12:135–146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y and Li J, Zhuge L, Su D, Yang M,
Tao S and Li J: Comparison between the efficacies of curcumin and
puerarin in C57BL/6 mice with steatohepatitis induced by a
methionine- and choline-deficient diet. Exp Ther Med. 7:663–668.
2014.PubMed/NCBI
|
|
21
|
Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du
ZY, Wang X, Shen JK and Peng HL: Long-term baicalin administration
ameliorates metabolic disorders and hepatic steatosis in rats given
a high-fat diet. Acta Pharmacol Sin. 30:1505–1512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu
D and Gao X: Berberine reduces methylation of the MTTP promoter and
alleviates fatty liver induced by a high-fat diet in rats. J Lipid
Res. 51:2504–2515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui W, Li X, Zhou S and Weng J:
Investigation on process parameters of electrospinning system
through orthogonal experimental design. J Appl Polym Sci.
103:3105–3112. 2007. View Article : Google Scholar
|
|
24
|
Khan F, Choong WL, Du Q and Jovanovi'c A:
Real-time RT-PCR Ct values for blood GAPDH correlate with measures
of vascular endothelial function in humans. Clin Transl Sci.
6:481–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matteoni CA, Younossi ZM, Gramlich T,
Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver
disease: A spectrum of clinical and pathological severity.
Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Adams LA and Angulo P: Treatment of
non-alcoholic fatty liver disease. Postgrad Med J. 82:315–322.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Day CP and James OF: Steatohepatitis: A
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Postic C and Girard J: Contribution of de
novo fatty acid synthesis to hepatic steatosis and insulin
resistance: Lessons from genetically engineered mice. J Clin
Invest. 118:829–838. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Law RE, Goetze S, Xi XP, Jackson S, Kawano
Y, Demer L, Fishbein MC, Meehan WP and Hsueh WA: Expression and
function of PPARgamma in rat and human vascular smooth muscle
cells. Circulation. 101:1311–1318. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harrison SA: Thiazolidinedione therapy for
nonalcoholic steatohepatitis: Go, stop, or proceed with caution?
Hepatology. 51:366–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ,
Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional
fibrosis and steatohepatitis in mice. Scand J Gastroenterol.
44:358–365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheatham B and Kahn CR: Cysteine 647 in
the insulin receptor is required for normal covalent interaction
between alpha-andbeta-subunits and signal transduction. J Biol
Chem. 267:7108–7115. 1992.PubMed/NCBI
|
|
33
|
Seino S and Bell GI: Alternative splicing
of human insulin receptor messenger RNA. Biochem Biophys Res
Commun. 159:312–316. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
El-Bassossy HM, Abo-Warda SM and Fahmy A:
Chrysin and luteolin alleviate vascular complications associated
with insulin resistance mainly through PPAR-γ activation. Am J Chin
Med. 42:1153–1167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shamsi BH, Ma C, Naqvi S and Xiao Y:
Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and
obesity related changes in mice. PLoS One. 9:e1069922014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang RC and Jiang DM: PPAR-γ agonist
pioglitazone affects rat gouty arthritis by regulating cytokines.
Genet Mol Res. 13:6577–6781. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Seeff LB, Lindsay KL, Bacon BR, Kresina TF
and Hoofnagle JH: Complementary and alternative medicine in chronic
liver disease. Hepatology. 34:595–603. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu RJ, Zhang YW, Wen CW and Tang J: Study
on the design and analysis methods of orthogonal experiment. Exp
Technol and Manage. 27:52–552010.
|
|
39
|
Silva RN, Bueno PG, Avó LR, Nonaka KO,
Selistre-Araújo HS and Leal AM: Effect of physical training on
liver expression of activin A and follistatin in a nonalcoholic
fatty liver disease model in rats. Braz J Med Biol Res. 47:746–752.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kucera O and Cervinkova Z: Experimental
models of non-alcoholic fatty liver disease in rats. World J
Gastroenterol. 20:8364–8376. 2014. View Article : Google Scholar : PubMed/NCBI
|
